VIEWS: 22 PAGES: 9 CATEGORY: Company Profiles POSTED ON: 8/20/2010
Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of neuronal nicotinic receptor (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target NNRs. As of December 31, 2010, it had a number of clinical-stage product candidates and preclinical programs. The Company has two collaborations with the pharmaceutical company, AstraZeneca, one a collaboration and license agreement focused on TC-5214, as a treatment for depressive disorder, and the other is a collaborative research and license agreement focused in cognitive disorders. As of December 31, 2010, the Company's advanced product candidates included TC-5214, TC-5619, AZD3480 (TC-1734), AZD1446, TC-6987, TC-6499 and Pentad.
Company Fundamentals\Company Profile A Wright Investors' Service Research Report: Targacept, Inc. 440 Wheelers Farms Road Milford, CT 06461 U.S.A. COMPANY PROFILE Figures in U.S. Dollars Wright Quality Rating:CANN Key Data Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery Ticker: and development of NNR Therapeutics for the treatment of diseases and disorders of TRGT the central nervous system. Its NNR Therapeutics focuses on neuronal nicotinic receptors (NNRs). The Company has a range of clinical-stage product candidates 2010 Sales: and preclinical programs, which includes TC-5214, AZD3480 (TC-1734) and AZD1446 85,713,000 (TC-6683), TC-5619, TC-6987, TC-6499 and TC-5685. The Company has preclinical research programs in smoking cessation, addiction, obesity, pain and Parkinson's disease. In addition, it has a program focused on the role of NNRs in inflammation Major Industry: involving the affecting of cytokines. The Company also has two collaborations with Drugs, Cosmetics & Health AstraZeneca, one focused on TC-5214 as a treatment for depressive disorder and Care one focused in cognitive disorders, as well as an alliance with GlaxoSmithKline. Stock Chart Officers Sub Industry: Chairman Ethical Drug Manufacturers Dr. Mark B. Skaletsky Country: President & Chief Executive United States Dr. J. Donald deBethizy Currency: Senior Vice President U.S. Dollars Finance, Chief Financial Officer & Treasurer Fiscal Year Ends: Alan A. Musso December Vice President Finance Mauri K. Hodges Employees 132 Senior Vice President, Secretary & General Counsel Exchanges: Peter A. Zorn Esq. NAS Share Type: Common Stock Price (7/29/2011): 20.44 Recent stock performance Market
Pages to are hidden for
"Targacept Company Profile - Aug 05, 2011"Please download to view full document